Apogee Therapeutics
APGE
182 hedge funds and large institutions have $2.51B invested in Apogee Therapeutics in 2025 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 55 increasing their positions, 65 reducing their positions, and 22 closing their positions.
73% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 22
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
9% more capital invested
Capital invested by funds: $2.3B → $2.51B (+$210M)
8% more funds holding
Funds holding: 168 → 182 (+14)
8.01% less ownership
Funds ownership: 133.61% → 125.6% (-8%)
15% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 65
46% less call options, than puts
Call options by funds: $18.5M | Put options by funds: $34.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$31.9M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$21.4M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$17.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$16.3M |
| 5 |
Goldman Sachs
New York
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$63.9M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$58.6M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$48.9M |
| 4 |
Mercer Global Advisors
Denver,
Colorado
|
-$31.2M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$22.6M |
APGE Hedge Fund Activity: Q2 2025 in Review
182 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Apogee Therapeutics (APGE) for Q2 2025, worth a combined $2.51B — up 9.1% from $2.3B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new APGE positions and 22 closed out — a net gain of 16 holders — while 55 added to existing stakes and 65 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $31.9M. The largest seller was Wellington Management Group, cutting an estimated $63.9M.
- 182 institutional investors held Apogee Therapeutics (APGE) as of Q2 2025, up from 168 in Q1 2025.
- Funds reported $2.51B of Apogee Therapeutics stock for Q2 2025, up 9.1% quarter-over-quarter.
- 38 funds opened new Apogee Therapeutics positions in Q2 2025 and 22 closed out, a net change of +16 holders.
- The largest Apogee Therapeutics buyer in Q2 2025 was Point72 Asset Management, an estimated $31.9M added.
- The largest Apogee Therapeutics seller in Q2 2025 was Wellington Management Group, an estimated $63.9M sold.
Based on aggregated 13F filings for Q2 2025.